- Home
- UROY vs TSHA Comparison
UROY vs TSHA Comparison
Compare UROY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- TSHA
- Stock Information
- Founded
- UROY 2017
- TSHA 2019
- Country
- UROY Canada
- TSHA United States
- Employees
- UROY N/A
- TSHA N/A
- Industry
- UROY
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- TSHA Health Care
- Exchange
- UROY Nasdaq
- TSHA Nasdaq
- Market Cap
- UROY 229.9M
- TSHA 262.4M
- IPO Year
- UROY N/A
- TSHA 2020
- Fundamental
- Price
- UROY $1.85
- TSHA $1.76
- Analyst Decision
- UROY Strong Buy
- TSHA Strong Buy
- Analyst Count
- UROY 2
- TSHA 8
- Target Price
- UROY $4.00
- TSHA $6.63
- AVG Volume (30 Days)
- UROY 3.4M
- TSHA 2.7M
- Earning Date
- UROY 03-06-2025
- TSHA 05-13-2025
- Dividend Yield
- UROY N/A
- TSHA N/A
- EPS Growth
- UROY N/A
- TSHA N/A
- EPS
- UROY N/A
- TSHA N/A
- Revenue
- UROY $15,984,827.00
- TSHA $8,333,000.00
- Revenue This Year
- UROY N/A
- TSHA N/A
- Revenue Next Year
- UROY $6.55
- TSHA N/A
- P/E Ratio
- UROY $339.12
- TSHA N/A
- Revenue Growth
- UROY N/A
- TSHA N/A
- 52 Week Low
- UROY $1.43
- TSHA $1.05
- 52 Week High
- UROY $3.12
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- UROY 54.49
- TSHA 61.26
- Support Level
- UROY $1.65
- TSHA $1.13
- Resistance Level
- UROY $1.89
- TSHA $1.98
- Average True Range (ATR)
- UROY 0.13
- TSHA 0.16
- MACD
- UROY 0.03
- TSHA 0.08
- Stochastic Oscillator
- UROY 91.30
- TSHA 76.34
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.